|
| Is PCSK9 therapy the solution to all cardiovascular disease?
|
|
In this editorial
Prof. Anthony S. Wierzbicki, Guy’s & St Thomas’ Hospitals, London, UK discusses his view of the evidence and what we still need to know about these novel treatments.
Read more » |
|
 |
Why PCSK9 inhibitors are needed in FH
Spanish SAFEHEART Registry shows the extent of poor LDL-cholesterol control despite high-intensity statin plus ezetimibe according to Prof. Derick Raal, University of the Witwatersrand, Johannesburg, South Africa.
Read more » |
|
 |
|
 |
|
News on the Congress Front
84th Congress of the European Atherosclerosis Society, May 29 - June 1, Innsbruck Austria.
PCSK9 Forum will be reporting with news and views from the experts.
Check back on www.pcsk9forum.org » |
|
|
New and updated edition of our popular therapeutic guide
 A second edition of the free introductory guide: PCSK9 Inhibition - New Therapies in Cardiovascular Risk Reduction is now available on the Forum’s website. This very popular book has been updated with the latest information discussing the biology and therapeutic potential of PCSK9 inhibition.
As you know, this downloadable e-book is freely available to all registered members of the Forum.
Read online » Download now »
Forward to colleagues » |
|
 |
|
|
|
Questions & Answers
Inhibition of PCSK9 offers the real possibility of improved management of high-risk patients.
Read the full answer and other questions on the PCSK9 Forum » |
|
|
For the latest updates, PCSK9 news and analysis. |
|
Hot topics, news and conference reports. |
|
For videos, interviews and webcasts from leading experts. |
|
|
|
